UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: December 20, 2023
(Commission File No. 001-39308)
CALLIDITAS THERAPEUTICS AB
(Translation of registrant’s name into
English)
Kungsbron 1, D5
SE-111 22
Stockholm, Sweden
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form
40-F ¨
INFORMATION CONTAINED IN THIS REPORT ON FORM
6-K
Enclosed hereto is a copy of an announcement published by Calliditas
Therapeutics AB on December 20, 2023.
The information contained in this Form 6-K, including Exhibit 99.1,
is hereby incorporated by reference into the registrant’s Registration Statements on Form F-3 (File No. 333-265881) and Form S-8
(File Nos. 333-240126 and 333-272594).
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
CALLIDITAS THERAPEUTICS AB |
|
|
|
Date: December 20, 2023 |
By: |
/s/ Fredrik Johansson |
|
|
Fredrik Johansson |
|
|
Chief Financial Officer |
Exhibit 99.1
Stockholm, Sweden |
December 20,
2023 |
Calliditas
Therapeutics announces full FDA approval of TARPEYO®, the only FDA- approved treatment for IgA nephropathy to significantly reduce
the loss of kidney function
Calliditas
Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), today announced that the U.S. Food and Drug
Administration (FDA) has approved TARPEYO (budesonide) delayed release capsules to reduce the loss of kidney function in adults with
primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. TARPEYO was first approved in December 2021 under
accelerated approval, based on the surrogate marker of proteinuria. Marking a significant milestone, TARPEYO is now the
first fully FDA-approved treatment for IgAN based on a measure of kidney function.
| · | TARPEYO
(investigational name NEFECON) is the only FDA-approved treatment for IgAN to significantly
reduce the loss of kidney function. |
| · | TARPEYO is now approved
with a confirmed and statistically significant benefit over placebo (p<0.0001) in estimated glomerular
filtration rate (eGFR) over the two-year period that consisted of 9 months of treatment with TARPEYO plus optimized renin-angiotensin
system inhibitor (RASi) or placebo and optimized RASi and 15 months of follow-up off study drug. |
| · | At
2 years, there was a 6.11 mL/min/1.73 m2 decline in eGFR in the TARPEYO group
compared with a 12.0 mL/min/1.73 m2 decline in the placebo group (p<0.0001),
representing 50% less deterioration of kidney function in TARPEYO-treated patients compared
to placebo-treated patients over the 2-year period. |
| · | TARPEYO
is a B-cell immunomodulator designed to target a source of the disease and reduce the production
of pathogenic galactose-deficient IgA1 antibodies, which cause IgAN.1-3 |
| · | Significant
proteinuria reduction achieved with TARPEYO plus RASi at 9 months was durable and maintained
throughout the 15-month off-drug period. |
| · | The
FDA approval is for adults with primary IgAN who are at risk of disease progression, irrespective
of proteinuria levels. |
“The evidence of sustained reductions
in proteinuria and a clinically significant reduction in the loss of eGFR, which can help slow the progression towards dialysis or
transplant care, highlights the potential of TARPEYO as a disease-modifying agent in IgAN,” said Richard Lafayette, MD, FACP,
Stanford Healthcare. “TARPEYO provides physicians and patients an effective treatment option to help improve disease
outcomes.”
The approval is based on data from the Company’s
Phase 3 NefIgArd clinical trial, a randomized, double- blind, multicenter, study that assessed the efficacy and safety of TARPEYO dosed
at 16 mg once daily versus placebo on a background of optimized RASi therapy in adult patients with primary IgAN.
"We are thrilled that adult IgAN
patients at risk for progression in the United States can now have access to this pioneering treatment option that could help
preserve their kidney function and, hence, impact the progression of their disease,” said Renee Aguiar-Lucander, CEO of
Calliditas. “This medicine was specifically developed to target an underlying cause of IgAN, and I would like to express my
gratitude to the Calliditas team, study investigators, and most importantly, the patients and caregivers who made this significant
milestone possible. I am incredibly proud of the team’s unwavering commitment to the goal of preventing end-stage renal
disease in patients with this challenging rare disease.”
TARPEYO was generally well-tolerated in the
Phase 3 NefIgArd clinical trial. The most common adverse reactions (≥5%) in this study were peripheral edema, hypertension,
muscle spasms, acne, headache, URT infection, face edema, weight increased, dyspepsia, dermatitis, arthralgia, and white blood cell
count increased. Please see Important Safety Information below.
"This first-ever IgAN treatment to get a full approval
based on kidney function represents a beacon of hope for the entire IgA nephropathy community and signifies a critical step forward in
the battle against IgAN,” said Bonnie Schneider, director and cofounder of the IgAN Foundation. “The foundation is elated
and personally this is so rewarding and validating after a near 20-year journey since founding this volunteer-run organization to raise
awareness and promote research for IgAN."
TARPEYO is available exclusively through
Calliditas specialty pharmacy, Biologics by McKesson. To get started with TARPEYO, prescribers must fill out a TARPEYO
Touchpoints® Enrollment Form, which serves as a prescription. This Enrollment Form will connect patients with all the benefits
provided by TARPEYO Touchpoints®, including financial aid programs that can eliminate or reduce out-of-pocket costs, assistance
from our team of care navigators, pharmacists, and nurse educators; and the convenience of at-home, next-day delivery. At
Calliditas, we believe that the cost of treatment should never be a barrier to care. With TARPEYO Touchpoints®, 97% of patients
taking TARPEYO have paid less than $10 per prescription, and 88% have paid nothing at all.
Indication
TARPEYO is indicated to reduce the loss of kidney function
in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.
Important Safety Information
Contraindications: TARPEYO is
contraindicated in patients with hypersensitivity to budesonide or any of the ingredients of TARPEYO. Serious hypersensitivity
reactions, including anaphylaxis, have occurred with other budesonide formulations.
Warnings and Precautions
Hypercorticism and adrenal axis
suppression: When corticosteroids are used chronically, systemic effects such as hypercorticism and adrenal suppression may
occur. Corticosteroids can reduce the response of the hypothalamus-pituitary-adrenal (HPA) axis to stress. In situations where
patients are subject to surgery or other stress situations, supplementation with a systemic corticosteroid is recommended. When
discontinuing therapy or switching between corticosteroids, monitor for signs of adrenal axis suppression.
Patients with moderate to severe hepatic impairment
(Child-Pugh Class B and C respectively) could be at an increased risk of hypercorticism and adrenal axis suppression due to an increased
systemic exposure to oral budesonide. Avoid use in patients with severe hepatic impairment (Child-Pugh Class C). Monitor for increased
signs and/or symptoms of hypercorticism in patients with moderate hepatic impairment (Child-Pugh Class B).
Risks of immunosuppression: Patients who
are on drugs that suppress the immune system are more susceptible to infection than healthy individuals. Chickenpox and measles, for
example, can have a more serious or even fatal course in susceptible patients or patients on immunosuppressive doses of
corticosteroids. Avoid corticosteroid therapy in patients with active or quiescent tuberculosis infection; untreated fungal,
bacterial, systemic viral, or parasitic infections, or ocular herpes simplex. Avoid exposure to active, easily-transmitted
infections (e.g., chicken pox, measles). Corticosteroid therapy may decrease the immune response to some vaccines.
Other corticosteroid effects: TARPEYO is a systemically
available corticosteroid and is expected to cause related adverse reactions. Monitor patients with hypertension, prediabetes, diabetes
mellitus, osteoporosis, peptic ulcer, glaucoma or cataracts, or with a family history of diabetes or glaucoma, or with any other condition
where corticosteroids may have unwanted effects.
Adverse reactions: In clinical
studies, the most common adverse reactions with TARPEYO (occurring in ≥5% of TARPEYO treated patients, and ≥2% higher
than placebo) were peripheral edema (17%), hypertension (12%), muscle spasms (12%), acne (11%), headache (10%), upper respiratory
tract infection (8%), face edema (8%), weight increased (7%), dyspepsia (7%), dermatitis (6%), arthralgia (6%), and white blood cell
count increased (6%).
Drug interactions: Budesonide is a substrate for
CYP3A4. Avoid use with potent CYP3A4 inhibitors, such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, erythromycin,
and cyclosporine. Avoid ingestion of grapefruit juice with TARPEYO. Intake of grapefruit juice, which inhibits CYP3A4 activity, can increase
the systemic exposure to budesonide.
Use in specific populations
Pregnancy: The available data from
published case series, epidemiological studies, and reviews with oral budesonide use in pregnant women have not identified a
drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. There are risks to the mother
and fetus associated with IgAN. Infants exposed to in-utero corticosteroids, including budesonide, are at risk for
hypoadrenalism.
Please see Full Prescribing Information.
About TARPEYO
TARPEYO is an oral 4mg delayed release formulation of
budesonide, designed to remain intact until it reaches the ileum. Each capsule contains coated beads of budesonide that target mucosal
B-cells present in the ileum, including the Peyer’s patches, which are responsible for the production of galactose- deficient IgA1
antibodies (Gd-Ag1) causing IgA nephropathy. 1-3
About the NeflgArd Study
NefIgArd was a global, Phase 3, randomized,
double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of TARPEYO 16 mg once daily vs placebo in adult
patients with primary IgAN (N=364) as an addition to optimized RASi therapy. Patients were randomized 1:1 to receive 16 mg/day oral capsules
of TARPEYO or matching placebo for 9 months, followed by a 15-month observational follow-up period without the study drug.
The primary efficacy endpoint was time-weighted average of
eGFR over 2 years. The time-weighted average of eGFR over 2 years showed a statistically significant treatment benefit with TARPEYO versus
placebo (difference 5·05 mL/min per 1·73 m² [95% CI 3·24 to 7·38], p<0·0001).
The favorable effect of TARPEYO on eGFR was seen by Month
3 (the earliest assessment) and did not appear to increase in magnitude over two years. At the end of Year 2, there was a 5.9 mL/min/1.73
m2 difference in the mean change from baseline in eGFR between TARPEYO and placebo (95% CI: 3.3 to 8.5 mL/min/1.73 m2;
p<0.0001). The effect on kidney function seen during the 9-month treatment period persisted following completion of treatment through
the end of the study but the overall effect on the long-term rate of decline has not been established.
The most common adverse reactions with
TARPEYO (occurring in ≥5% of TARPEYO treated patients and ≥2% higher than placebo) were peripheral edema (17%),
hypertension (12%), muscle spasms (12%), acne (11%), headache (10%), upper respiratory tract infection (8%), face edema (8%), weight
increase (7%), dyspepsia (7%), dermatitis (6%), arthralgia (6%), and white blood cell count increase (6%).
About Primary Immunoglobulin A Nephropathy
Primary immunoglobulin A nephropathy (IgAN
or Berger’s Disease) is a rare, progressive, chronic autoimmune disease that attacks the kidneys and occurs when
galactose-deficient IgA1 is recognized by autoantibodies, creating IgA1 immune complexes that become deposited in the glomerular
mesangium of the kidney.2,4 This deposition in the kidney can lead to progressive kidney damage and potentially a
clinical course resulting in end- stage renal disease. IgAN most often develops between the late teens and late
30s.2,5
For further information, please contact:
Åsa Hillsten, Head of IR and Sustainability, Calliditas
Tel.: +46 76 403 35 43, email: asa.hillsten@calliditas.com
The information in the press release is information that
Calliditas is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the
agency of the contact person set out above, on December 20, 2023 at 22:15 p.m. CET.
About Calliditas
Calliditas Therapeutics is a biopharma company headquartered
in Stockholm, Sweden, focused on identifying, developing, and commercializing novel treatments in orphan indications with significant
unmet medical needs.
Calliditas is listed on Nasdaq Stockholm (ticker: CALTX)
and the Nasdaq Global Select Market (ticker: CALT).
Visit Calliditas.com for further information.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation,
statements regarding Calliditas’ strategy, business plans, regulatory submissions, and focus. The words “may,”
“will,” “could,” “would,” “should,” “expect,” “plan,”
“anticipate,” “intend,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “target,” and similar expressions are intended
to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any
forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to
a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those
expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related
to Calliditas’ business, operations, continued FDA approval for TARPEYO, market acceptance of TARPEYO, clinical trials, supply
chain, strategy, goals and anticipated timelines, competition from other biopharmaceutical companies, and other risks identified in
the section entitled “Risk Factors” in Calliditas’ reports filed with the Securities and Exchange Commission.
Calliditas cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are
made. Calliditas disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or
in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual
results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press
release represent Calliditas’ views only as of the date hereof and should not be relied upon as representing its views as of
any subsequent date.
1. TARPEYO. Prescribing Information. Calliditas Therapeutics AB; 2023.
2.
Barratt J, Rovin BH, Cattran D, et al. Why target the gut to treat IgA nephropathy? Kidney Int Rep. 2020;5(10):1620-1624.
doi:10.1016/j.ekir.2020.08.009
3.
Fellström BC, Barratt J, Cook H, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN):
a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017;389(10084):2117-2127. doi:10.1016/S0140-6736(17)30550-0
4.
Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol. 2005;16(7):2088-2097. https://doi.org/10.1681/ASN.2005020134
5.
Jarrick S, Lundberg S, Welander A, et al. Mortality in IgA nephropathy: a nationwide population-based cohort study. J Am Soc
Nephrol. 2019;30(5):866-876. https://doi.org/10.1681/ASN.2018101017
Calliditas Therapeutics AB (NASDAQ:CALT)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Calliditas Therapeutics AB (NASDAQ:CALT)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024